# ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma

> **NCT03322813** · NA · SUSPENDED · sponsor: **InSightec** · enrollment: 15 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DEVICE:** ExAblate 4000 - Type 2

## Key facts

- **NCT ID:** NCT03322813
- **Lead sponsor:** InSightec
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-10
- **Primary completion:** 2024-09
- **Final completion:** 2024-12
- **Target enrollment:** 15 (ESTIMATED)
- **Why stopped:** Study temporarily suspended until priorities are reassessed
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322813, "ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03322813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*